Search Results - "Ladická, Miriam"

Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration by Sýkorová, Alice, Folber, František, Polgárová, Kamila, Móciková, Heidi, Ďuraš, Juraj, Steinerová, Kateřina, Obr, Aleš, Heindorfer, Adriana, Ladická, Miriam, Lukáčová, Ľubica, Čellárová, Erika, Plameňová, Ivana, Belada, David, Janíková, Andrea, Trněný, Marek, Jančárková, Tereza, Procházka, Vít, Vranovský, Andrej, Králiková, Margaréta, Vydra, Jan, Smolej, Lukáš, Drgoňa, Ľuboš, Sedmina, Martin, Čermáková, Eva, Pytlík, Robert

“…Aim The aim of this study was to analyse the outcomes of patients with large B‐cell lymphoma (LBCL) treated with chimeric antigen receptor T‐cell therapy…”
Get full text

Ibrutinib treatment of mantle cell lymphoma complicated by progressive multifocal leukoencephalopathy by Mosna, Kristina, Ladicka, Miriam, Drgona, Lubos, Vranovska, Martina, Hojsikova, Ivana, Tomasova, Radka, Danihel, Jr, Ludovit, Kyselovic, Jan, Babal, Pavel

“…Progressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease of the central nervous system, caused by reactivation of John Cunningham…”
Get full text

Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia by Král, Zdeněk, Michalka, Jozef, Móciková, Heidi, Marková, Jana, Sýkorová, Alice, Belada, David, Jungová, Alexandra, Vokurka, Samuel, Lukášová, Marie, Procházka, Vít, Ďuraš, Juraj, Hájek, Roman, Dušek, Ladislav, Drgoňa, Ľuboš, Ladická, Miriam, Ballová, Veronika, Vranovský, Andrej

“…Introduction: Clinical trials have demonstrated the effectiveness of the CD30-targeted antibody-drug conjugate brentuximab vedotin (BV) for the treatment of…”
Get full text

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial by Egle, Alexander, Melchardt, Thomas, Obrtlíková, Petra, Smolej, Lukáš, Kozák, Tomáš, Steurer, Michael, Andel, Johannes, Burgstaller, Sonja, Mikušková, Eva, Gercheva, Liana, Nösslinger, Thomas, Papajík, Tomáš, Ladická, Miriam, Girschikofsky, Michael, Hrubiško, Mikuláš, Jäger, Ulrich, Voskova, Daniela, Pecherstorfer, Martin, Králiková, Eva, Burcoveanu, Christina, Spasov, Emil, Petzer, Andreas, Mihaylov, Georgi, Raynov, Julian, Oexle, Horst, Zabernigg, August, Flochová, Emília, Palášthy, Stanislav, Stehlíková, Olga, Doubek, Michael, Altenhofer, Petra, Weiss, Lukas, Magnes, Teresa, Pleyer, Lisa, Klingler, Anton, Mayer, Jiří, Greil, Richard

“…No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL‐8a Mabtenance trial for…”
Get full text

Single Institution Experience with Nivolumab in Treatment of Patients with Relapsed or Refractory Hodgkin’s Lymphoma by Kašperová, Barbora, Ladická, Miriam, Drgoňa, Ľuboš, Greksák, Radoslav, Bizikova, Ivona, Fekete, Ladislav, Rázus, Martin, Vranovský, Andrej

Get full text

Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting by Ludwig, Heinz, Ramasamy, Karthik, Mateos, María-Victoria, Kishore, Bhuvan, Gergely, Varga, Ladicka, Miriam, Ori, Alessandra, Simoni, Lucia, Bent-Ennakhil, Nawal, Stull, Dawn Marie, Gavini, François, Terpos, Evangelos, Hájek, Roman

“…In multiple myeloma (MM), improving our understanding of routine clinical practice and the effectiveness of agents outside of clinical trials is important…”
Get full text

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial by Greil, Richard, Prof, Obrtlíková, Petra, MD, Smolej, Lukáš, MD, Kozák, Tomáš, Prof, Steurer, Michael, Prof, Andel, Johannes, MD, Burgstaller, Sonja, MD, Mikušková, Eva, MD, Gercheva, Liana, Prof, Nösslinger, Thomas, MD, Papajík, Tomáš, Prof, Ladická, Miriam, MD, Girschikofsky, Michael, MD, Hrubiško, Mikuláš, Prof, Jäger, Ulrich, Prof, Fridrik, Michael, MD, Pecherstorfer, Martin, Prof, Králiková, Eva, MD, Burcoveanu, Cristina, MD, Spasov, Emil, MD, Petzer, Andreas, Prof, Mihaylov, Georgi, MD, Raynov, Julian, MD, Oexle, Horst, MD, Zabernigg, August, MD, Flochová, Emília, MD, Palášthy, Stanislav, MD, Stehlíková, Olga, Doubek, Michael, Prof, Altenhofer, Petra, MD, Pleyer, Lisa, MD, Melchardt, Thomas, MD, Klingler, Anton, PhD, Mayer, Jiří, Prof, Egle, Alexander, MD

“…Summary Background In many patients with chronic lymphocytic leukaemia requiring treatment, induction therapy with rituximab plus chemotherapy improves…”
Get full text

Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial by Greil, Richard, Obrtlikova, Petra, Smolej, Lukas, Kozak, Tomas, Steurer, Michael, Andel, Johannes, Thaler, Josef, Mikuskova, Eva, Gercheva, Liana, Nösslinger, Thomas, Ladicka, Miriam, Girschikofsky, Michael, Hrubiko, Mikulá, Jäger, Ulrich, Fridrik, Michael A., Pecherstorfer, Martin, Kralikova, Eva, Burcoveanu, Cristina, Goranov, Stefcho, Jurkovikova, Jana, Petzer, Andreas L., Mihaylov, Georgi G., Raynov, Julian, Oexle, Horst, Zabernigg, August, Flochova, Emilia, Palasthy, Stanislav, Melchardt, Thomas, Mayer, Jiri, Egle, Alexander

“…▪ Introduction: Chemoimmunotherapy has become a standard approach in previously untreated and also in pretreated CLL. Addition of Rituximab to FC in fit…”
Get full text